Annotating nodes for druggability adds an additional dimension to the interpretation of the network, specifically identifying TFs (that is, E2F1, SP3, NFκB1, PGR and SMAD6) that can be targeted by approved anti-cancer drugs, presenting the possibility for intervening pharmaceutically to change the activity of these regulatory sub-networks. The gene discussed is SP3; the disease is cancer.